Factors for Rituximab Refractoriness in AQP4 ‐ IgG + NMOSD : A Cohort Study
Annals of Clinical and Translational Neurology · 2025-08 · 12 (8) · 1566-1574
DOI: 10.1002/acn3.70095 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 10.06.2025. Verfasst von Mariano Marrodan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Departamento de Neurología, Fleni, Buenos Aires, Argentina. Hauptthemen laut MEDLINE: Rituximab, Neuromyelitis Optica, Aquaporin 4, Immunologic Factors. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.
Abstract (Originalsprache)
Objective
Neuromyelitis optica spectrum disorder (NMOSD) is a severe autoimmune condition of the central nervous system (CNS), often associated with aquaporin‐4 antibodies (AQP4‐IgG). Rituximab, a CD20+ B‐cell depleting monoclonal antibody, is widely used as first‐line therapy. However, a subset of patients exhibits treatment refractoriness. Our objective is to investigate factors associated with treatment refractoriness in AQP4‐IgG‐positive NMOSD patients treated with rituximab.
Methods
This retrospective cohort study included 54 AQP4‐IgG‐positive NMOSD patients treated with rituximab between 2006 and 2023. Clinical, imaging, and genetic data were analyzed. Treatment failure was defined as at least one relapse occurring after 6 months of rituximab initiation. Statistical analyses included multivariate analyses of covariance (MANCOVA) and Cox regression to identify independent predictors of treatment failure.
Results
Among the 54 patients (82.5% female, median age 45 years, range: 34–54.5), 12 (22.2%) exhibited rituximab treatment failure. The presence of asymptomatic lesions during follow‐up was significantly associated with treatment failure ( p = 0.02) and emerged as an independent predictor in MANCOVA (Wilks' Lambda = 0.01, F = 20.5, η 2 = 0.357, p < 0.001). These lesions also increased the risk of clinical relapses (HR = 25.9, 95% CI = 3.09–218, p < 0.01). Other variables, including age, sex, baseline EDSS, and persistent gadolinium enhancement, were not significantly associated with treatment failure. Genetic analysis of the FCGR3A‐V158F polymorphism did not reveal a significant relationship with treatment outcomes.
Interpretation
Asymptomatic lesions during rituximab treatment are a strong predictor of therapeutic failure in AQP4‐IgG‐positive NMOSD patients. Early identification of these lesions could guide clinicians in optimizing treatment strategies, including transitioning to alternative therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Departamento de Neurología, Fleni, Buenos Aires, Argentina.
- Centro de Investigación en Enfermedades Neuroinmunológicas (CIEN), Fleni, Buenos Aires, Argentina.
- Laboratorio de Enfermedades Neurodegenerativas, Instituto de Neurociencias Fleni-CONICET (Consejo Nacional de Investigaciones Científicas y Tecnológicas), Buenos Aires, Argentina.
- Instituto de Química y Fisicoquímica Biológicas (IQUIFIB), CONICET/Universidad de Buenos Aires, Buenos Aires, Argentina.
ORCID-Profile: Mariano Marrodan, Ezequiel I Surace
Förderung
- AstraZeneca
Zitieren
APA
Marrodan, M., Piedrabuena, M. A., Zarate, M. A., Rodríguez Murúa, S., Surace, E. I., Farez, M. F., Fiol, M. P., Ysrraelit, M. C., & Correale, J. (2025). Factors for Rituximab Refractoriness in AQP4 ‐ IgG + NMOSD : A Cohort Study. Annals of Clinical and Translational Neurology, 12(8), 1566-1574. https://doi.org/10.1002/acn3.70095
Vancouver
Marrodan M, Piedrabuena MA, Zarate MA, Rodríguez Murúa S, Surace EI, Farez MF, et al. Factors for Rituximab Refractoriness in AQP4 ‐ IgG + NMOSD : A Cohort Study. Annals of Clinical and Translational Neurology. 2025;12(8):1566-1574. doi:10.1002/acn3.70095
BibTeX
@article{Marrodan2025,
author = {Marrodan, Mariano and Piedrabuena, María A and Zarate, María A and Rodríguez Murúa, Sofía and Surace, Ezequiel I and Farez, Mauricio F and Fiol, Marcela P and Ysrraelit, María C and Correale, Jorge},
title = {Factors for Rituximab Refractoriness in AQP4 ‐ IgG + NMOSD : A Cohort Study},
journal = {Annals of Clinical and Translational Neurology},
year = {2025},
volume = {12},
number = {8},
pages = {1566--1574},
doi = {10.1002/acn3.70095}
}
EUVIMED